Technical Analysis for THRX - Theseus Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
C 15.9 -0.69% -0.11
THRX closed down 0.69 percent on Monday, October 18, 2021, on 20 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A N/A
Historical THRX trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
New 52 Week Closing Low Bearish 10.88%
Hot IPO Pullback Bullish Swing Setup 10.88%
New 52 Week Low Weakness 10.88%
Outside Day Range Expansion 10.88%
Down 3 Days in a Row Weakness 10.88%
Down 4 Days in a Row Weakness 10.88%
Down 5 Days in a Row Weakness 10.88%
New 52 Week Closing Low Bearish 2.58%
Older End-of-Day Signals for THRX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Theseus Pharmaceuticals, Inc. Description

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus' lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).


Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Chemical Compounds Organic Compounds Non Small Cell Lung Cancer Targeted Therapy Epidermal Growth Factor Receptor Tyrosine Kinase Lung Cancer Protein Kinase Inhibitor Non Small Cell Lung Carcinoma Advanced Gastrointestinal Stromal Tumors

Is THRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 24.54
52 Week Low 13.71
Average Volume 426,422
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 0.00
10-Day Moving Average 0.00
Average True Range 0.00
ADX 0.0
+DI 0.00
-DI 0.00
Chandelier Exit (Long, 3 ATRs) N/A
Chandelier Exit (Short, 3 ATRs) N/A
Upper Bollinger Bands 0.00
Lower Bollinger Band 0.00
Percent B (%b) 0.0
BandWidth 0.00
MACD Line 0.00
MACD Signal Line 0.00
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.77
Resistance 3 (R3) 16.74 16.43 16.63
Resistance 2 (R2) 16.43 16.21 16.44 16.58
Resistance 1 (R1) 16.16 16.07 16.01 16.19 16.53
Pivot Point 15.85 15.85 15.77 15.86 15.85
Support 1 (S1) 15.58 15.63 15.43 15.61 15.27
Support 2 (S2) 15.27 15.49 15.28 15.22
Support 3 (S3) 15.00 15.27 15.18
Support 4 (S4) 15.03